Last reviewed · How we verify
NCT03185845
The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism
NA trial testing Warfarin in COPD Exacerbation in 392 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 392 |
| Start date | 15 June 2017 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Warfarin (warfarin) — full drug profile →
Conditions studied
- COPD Exacerbation — all drugs for COPD Exacerbation →
- PTE - Pulmonary Thromboembolism — all drugs for PTE - Pulmonary Thromboembolism →
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Who can join
40 and older, any sex, with COPD Exacerbation or PTE - Pulmonary Thromboembolism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Anticoagulation is the most important treatment for pulmonary thromboembolism (PTE). The thromboembolism risk is especially high in patients with chronic obstructive pulmonary disease (COPD) exacerbations. However, there's no agreement on the most appropriate duration of anticoagulation in COPD with PTE to balance the risk of recurrence of thrombosis and bleeding. This randomized, controlled trial aims to evaluate the risk and benefit of prolonged anticoagulation compared with the regular 3-month anticoagulation in COPD with PTE.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03185845
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Warfarin
Trials testing the same drug.
- NCT07502001 — Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin · Phase 1 · not yet recruiting
- NCT07456085 — Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves · Phase 3 · enrolling by invitation
- NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting
- NCT05643651 — Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease · Phase 4 · recruiting
- NCT07358416 — Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery. · active not recruiting
Other recruiting trials for COPD Exacerbation
Currently open trials in the same condition.
- NCT07351929 — Emotional-distress-based Integrated Care Programme in Patients With an Acute Exacerbation of COPD · NA · recruiting
- NCT05703919 — Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease · Phase 4 · recruiting
- NCT06347536 — Supported Rescue Packs Post-discharge in Chronic Obstructive Pulmonary Disease · Phase 3 · recruiting
- NCT06691399 — Role of Oral Care in Prevention of Nosocomial Pneumonia Among COPD Patients · NA · recruiting
- NCT05958563 — Impact of Continuous Positive Airway Pressure on the Occurrence of Acute Exacerbations of COPD in Patients With COPD-OSA · NA · recruiting
Other Chinese Academy of Medical Sciences, Fuwai Hospital trials
Trials by the same sponsor.
- NCT07450196 — A Prospective, Multicenter, Observational Study Evaluating Safety and Effectiveness of SAPIEN 3 Transcatheter Aortic Val · not yet recruiting
- NCT07511309 — FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07054541 — A Novel Echocardiography-Guided Strategy for Percutateous Closure of Atrial Septal Defect Assisted by PannaWire · Phase 4 · not yet recruiting
- NCT07458672 — TAVR for Aortic Regurgitation Under TTE Guidance · NA · not yet recruiting
- NCT07462325 — Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03185845 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences, Fuwai Hospital
- Last refreshed: 14 June 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03185845.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing